Lexaria Bioscience Bolsters Drug Delivery Strategy

Lexaria Bioscience (LEXX) has released an update.

Lexaria Bioscience has formed a new Scientific Advisory Board to enhance its drug delivery platform technology, with John Docherty, a seasoned expert in the pharmaceutical sector, as the Chairman. The board, comprising experts in pharmaceutical development, aims to guide the company’s strategic plans towards successful commercialization.

For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.